Project Grant R35HL177123
Award Date
5/1/25
Completion Date
4/30/32
Dollars Obligated
$1.1M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Milwaukee, WI 53226, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is focused on studying the molecular mechanisms by which progranulin, an anti-inflammatory protein, regulates endothelial cell function and blood pressure control. The $1,568,003 award, with a project period from September 2024 to April 2029, aims to determine if reduced endothelial progranulin levels contribute to the development and progression of hypertension...
This $827,665 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837) supports research to develop scalable methods for identifying causal genetic variants, relevant cell types, and target genes that influence cardiovascular disease (CVD) risk. The key products and services to be delivered include: Performing colocalization of CVD and blood cell trait genome-wide association studies (GWAS) to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded Temple University a $732,119 project grant under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837) to study the role of the vascular enzyme pyruvate kinase M2 (PKM2) in hypertension and associated vascular remodeling. The 4-year project, running from December 2024 to November 2028, aims to investigate how PKM2 activation in vascular smooth muscle cells (VSMCs) contributes to hypertension development and vascular...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) totals $717,773.00 and will be conducted from July 1, 2024 to June 30, 2028. The award will support research to investigate the role of Pannexin 1 (PANX1) and Piezo1 channels in regulating renin release, a key process in the renin-angiotensin-aldosterone system that controls blood pressure. The research will focus on understanding the mechanistic...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $717,236 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Iowa to study the role of neuronal primary cilia in hypertension, autonomic dysfunction, and body fluid imbalance. The key products and services to be delivered under this 4-year grant include: Evaluating how conditional ablation of cilia in the supraoptic nucleus affects blood pressure, drinking, urine volume, sodium concentration, plasma...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,454,955 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Beckman Research Institute of the City of Hope. The funding will support research to characterize the role of the RPS6KB1 protein as an integrative player in the pathological cardiac remodeling that occurs in hypertensive heart disease and heart failure. Key components of the research include further studying the mechanisms of RPS6KB1...
This $378,450 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports research to define the genetic causes of primary aldosteronism (PA), a common form of endocrine hypertension, in Black American patients. The project aims to: Identify novel somatic mutations that drive aldosterone excess and hypertension in Black American PA patients through next-generation sequencing of adrenal...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA program 93.837 Cardiovascular Diseases Research is providing $807,948 to support a study on the genetics of left ventricular hypertrophy (LVH) and associated cardiac phenotypes. The primary awardee, The Medical College of Wisconsin, Inc. (MCW), will utilize whole genome sequencing data from the NHLBI TOPMed program to conduct association analyses and identify genetic variants related to LVH....
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), provides $136,350 to Georgia State University Research Foundation Inc. to investigate the role of arterial baroreceptors in the development of hypertension. The award is funded under the Cardiovascular Diseases Research program (CFDA 93.837), which supports research aimed at understanding, preventing, diagnosing, and treating cardiovascular conditions. The project...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $131,485 to Brigham & Women's Hospital Inc. to conduct research on understanding the role of proline metabolism dysregulation in the development of pulmonary arterial hypertension (PAH). The key objectives of the research project are to 1) establish the regulation of proline availability and fibroproliferative...